Connect your AI

Edwards Lifesciences EW Stock-Based Comp

Stock-Based Comp at other companies

AbbottABT

$168M+18.3%

ArtivionAORT

$8.41M+4.6%

Merit Medical SystemsMMSI

$8.96M-1.3%

ICU MedicalICUI

$14.01M+15.0%

Boston ScientificBSX

$83M+12.2%

LeMaitre VascularLMAT

$2.09M+2.2%

Other financials

Income statement

Revenue$1.7B+13.6%

Gross profit$1.3B+13.5%

Operating income$513.2M+24.8%

Net income$241.9M-27.4%

EPS (diluted)$0.42-25.0%

Balance sheet

Cash & equivalents$2.4B-22.3%

Total debt$702.9M+0.5%

Total equity$10.3B+2.0%

Total assets$13.3B+2.3%

Cash flow

Operating cash flow$43.8M-84.4%

CapEx$64.9M+15.9%

Free cash flow-$21.1M-109%

Valuation

Market cap$48.18B+3.7%

Enterprise value$46.44B+11.0%

P/E48×+36.7×

P/S7.4×-0.8×

Profitability

Gross margin77.8%-1.0pp

Operating margin22.3%-3.6pp

Net margin15.4%-57.5pp

FCF margin17.3%—

Returns & leverage

Return on equity10.7%-37.8pp

Debt / equity0.1×0.0×

Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edwards Lifesciences's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Edwards Lifesciences's stock-based comp?: Edwards Lifesciences (EW) reported stock-based comp of $45.4M in Q1 2026.
How has Edwards Lifesciences's stock-based comp changed year-over-year?: Edwards Lifesciences's stock-based comp increased by 12.9% year-over-year, from $40.2M to $45.4M.
What is the long-term trend for Edwards Lifesciences's stock-based comp?: Over 4 years (2021 to 2025), Edwards Lifesciences's stock-based comp has grown at a 9.7% compound annual growth rate (CAGR), from $109.3M to $158.1M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.